A Shimoni

Summary

Country: Israel

Publications

  1. ncbi request reprint Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Exp Hematol 35:534-40. 2007
  2. doi request reprint Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced
    A Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 27:829-35. 2013
  3. doi request reprint Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
    A Shimoni
    Department of Bone Marrow Transplantation, The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 47:1274-82. 2012
  4. doi request reprint A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer 118:4706-14. 2012
  5. ncbi request reprint Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 41:355-61. 2008
  6. ncbi request reprint Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 20:322-8. 2006
  7. ncbi request reprint Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 21:2109-16. 2007
  8. ncbi request reprint Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:2110-20. 2007
  9. ncbi request reprint Mobilization regimens prior to stem-cell collection in patients with lymphoma: how to choose?
    Avichai Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:1888-90. 2007
  10. ncbi request reprint Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes
    Avichai Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:2352-9. 2007

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Exp Hematol 35:534-40. 2007
    ..To determine the safety and outcome following standard-dose ibritumomab tiuxetan followed by BEAM high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma...
  2. doi request reprint Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced
    A Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 27:829-35. 2013
    ..Patients and physicians should be aware of this association and life-long cancer screening is required for all transplant survivors...
  3. doi request reprint Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
    A Shimoni
    Department of Bone Marrow Transplantation, The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 47:1274-82. 2012
    ..02). FT is an RTC regimen with intensive anti-leukemia effect in MAC non-eligible patients...
  4. doi request reprint A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer 118:4706-14. 2012
    ..This is a randomized study evaluating the safety and efficacy of standard-dose ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy (Z-BEAM) and ASCT in refractory/relapsed aggressive lymphoma...
  5. ncbi request reprint Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 41:355-61. 2008
    ..The low incidence of relapse suggests augmented anti-lymphoma effect. Zevalin-RIC merits further study. Better results may be achieved in patients earlier in disease course and with longer duration of immune-suppression...
  6. ncbi request reprint Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 20:322-8. 2006
    ..02). Patients with active disease, ineligible for standard myeloablation, could tolerate modified myeloablation well; however, long-term outcome cannot be determined yet...
  7. ncbi request reprint Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 21:2109-16. 2007
    ..The FM regimen is more myelosuppressive and toxic but controls disease better. FB was associated with improved survival in patients transplanted in remission. These observations merit further study in prospective studies...
  8. ncbi request reprint Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:2110-20. 2007
    ..Preliminary results are promising and suggest improved disease control with no added toxicity; however randomized studies are needed to confirm these initial observations...
  9. ncbi request reprint Mobilization regimens prior to stem-cell collection in patients with lymphoma: how to choose?
    Avichai Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:1888-90. 2007
  10. ncbi request reprint Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes
    Avichai Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leuk Lymphoma 48:2352-9. 2007
    ....
  11. doi request reprint Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer 116:3621-30. 2010
    ..The role and timing of allogeneic SCT in the disease course remains controversial. To the authors' knowledge, there are limited data regarding the long-term outcome of RIC in the recurrent/refractory setting...
  12. doi request reprint Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Best Pract Res Clin Haematol 24:369-79. 2011
    ..A search for novel regimens or post-transplant approaches with more intensive anti-leukemic activity, but limited toxicity will also be of marked benefit...
  13. ncbi request reprint Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
    A Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 19:7-12. 2005
    ..Favorable outcome was observed in patients with myeloid malignancies, and those transplanted in remission and early in the course of disease. Age alone should not be considered a contraindication to unrelated donor SCT...
  14. ncbi request reprint Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity
    Avichai Shimoni
    Department of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Exp Hematol 31:428-34. 2003
    ..This study was designed to define the role of IV busulfan in different transplant and disease settings...
  15. ncbi request reprint Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Haematol 112:93-104. 2004
    ..Immunotherapy is more effective for MRD than at frank relapse. Timing and dosing of therapy are not yet well established and depend on aggressiveness of the disease, type of conditioning, level and kinetics of MRD...
  16. ncbi request reprint Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma
    Avichai Shimoni
    The Department of Haematology and Bone Marrow Transplantation, Chaim Sheba Medical Centre, Tel Hashomer, Israel
    Br J Haematol 122:457-64. 2003
    ..Rituximab may be an effective adjuvant therapy after SCT to reduce the relapse rate and improve the outcome in high-risk aggressive lymphoma. Larger scale comparative trials are necessary to better define its role in SCT...
  17. ncbi request reprint Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience
    Avichai Shimoni
    Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Curr Hematol Rep 3:242-8. 2004
    ....
  18. ncbi request reprint Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced
    Avichai Shimoni
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Biol Blood Marrow Transplant 10:484-93. 2004
    ..Further exploration of novel preventive and therapeutic measurements is required in high-risk settings...
  19. ncbi request reprint Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias
    A Shimoni
    Department of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 17:290-7. 2003
    ..Imatinib may have substantial activity in combination with DLI. Further study of a larger group of patients is required to assess the impact on long-term outcome and the role of post-transplant imatinib in controlling residual disease...
  20. doi request reprint Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
    I Danylesko
    Hematology and Bone Marrow Transplantation Division, Department of Hematology and Bone Marrow Transplantation, Laboratory of Molecular Immunobiology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 47:5-14. 2012
    ..Promising results were seen in myelodysplastic syndrome (survival 36-70%) and leukemia in remission (60-70%). Randomized prospective studies will be needed to better define the role of treosulfan-based regimens in SCT...
  21. ncbi request reprint Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis
    A Shimoni
    Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Leukemia 16:1413-8; discussion 1419-22. 2002
    ..The system also allows chimerism testing after sex-mismatched transplants, within cellular subsets, with no need for sorting of cells. The system merits further study in larger scale trials...
  22. ncbi request reprint Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation
    A Inbal
    Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 34:459-63. 2004
    ..Our results suggest that allo-SCT is not associated with increased hypercoagulability and addition of ATG to conditioning regimen has no significant procoagulant effect...
  23. pmc CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract
    A Shimoni
    Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Affiliated to Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Br J Radiol 85:e416-23. 2012
    ..To determine the role of abdominal CT in assessment of severity and prognosis of patients with acute gastrointestinal (GI) graft-vs-host disease (GVHD)...
  24. doi request reprint Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
    A Avigdor
    Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Ann Oncol 21:126-32. 2010
    ..This study was conducted in an attempt to reduce the toxicity of the original schedule, while attempting to preserve improved initial tumor control...
  25. ncbi request reprint Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice
    Avichai Shimoni
    Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer Treat Res 110:113-36. 2002
    ..This effort will focus on specific induction of HVG tolerance followed by induction of tumor-specific GVT effect to cure the underlying malignancy...
  26. pmc Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors
    Olga Ostrovsky
    Laboratory of Molecular Immunobiology, Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Blood 115:2319-28. 2010
    ....
  27. doi request reprint Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience
    M Yeshurun
    Department of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Beilinson Campus, 49100, Petah Tiqva, Israel
    Infection 38:211-5. 2010
    ..Recipients of hematopoietic stem-cell transplantation (HSCT) are at high risk for infections caused by Stenotrophomonas maltophilia...
  28. doi request reprint A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation
    Arnon Nagler
    Institute of Hematology, Tel Hashomer, Israel
    J Immunother 33:326-33. 2010
    ..These results suggest that outpatient administered immunotherapy with IFN-alpha and rIL-2 is relatively well tolerated and may intensify remission in NHL patients, but not HL patients after AutoSCT...
  29. doi request reprint Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
    Michal J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Clin Cancer Res 16:2646-55. 2010
    ..The purpose of this study is to explore the efficacy and toxicity of adoptively transferred Young-TIL following lympho-depleting chemotherapy in metastatic melanoma patients, refractory to interleukin-2 and chemotherapy...
  30. ncbi request reprint Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis
    Izhar Hardan
    Department of Bone Marrow Transplantation, Hematology and the Sheba Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Exp Hematol 32:254-60. 2004
    ..We suggest this technique as a novel sensitive and specific method for detection of del13q in a minor PC population of MM patients...
  31. doi request reprint Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
    Michal J Besser
    The Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 32:415-23. 2009
    ..The use of minimally cultured, unselected Young-TIL enables the treatment of most enrolled patients. Although the cohort of Young-TIL patients treated so far is rather small and the follow-up short, the response rate is encouraging...
  32. ncbi request reprint Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders
    Avichai Shimoni
    Department of Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 4:272-9. 2002
  33. doi request reprint Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    Raanan Berger
    Institute of Oncology and Radiotherapy, Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Clin Cancer Res 14:3044-51. 2008
    ..The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies...
  34. ncbi request reprint Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors
    Ninette Amariglio
    Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Haematol 117:68-73. 2007
    ..Conclusion: The administration of G-CSF is associated with transient DNA and gene expression modifications in the lymphocytes of normal mobilized donors. A long-term follow-up of stem cell donors is recommended...
  35. ncbi request reprint Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells
    M Leiba
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, and Sackler Medical School, Tel Aviv University, Isreal
    J Leukoc Biol 80:399-406. 2006
    ..It also inhibited DTH response in vivo, making it an attractive immunomodulator and anti-inflammatory agent...
  36. ncbi request reprint A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)
    Maya Koren-Michowitz
    Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
    Leuk Res 32:421-7. 2008
    ..97, p<0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients...
  37. ncbi request reprint BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma
    Ofer Margalit
    Pediatric Hematology Oncology, Safra Children s Hospital, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Blood 107:1599-607. 2006
    ..The increase in BCL6 mRNA levels was attenuated by the p53 inhibitor PFT-alpha. Thus, we define the BCL6 gene as a new p53 target, regulated through a RE frequently disrupted in BNHL...
  38. ncbi request reprint Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
    Charles Crawley
    Clinical Haematology, Box 234, Addenbrookes Hospital, Cambridge, CB2 2QQ, United Kingdom
    Blood 105:4532-9. 2005
    ..While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit...
  39. ncbi request reprint Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Germany
    Biol Blood Marrow Transplant 10:698-708. 2004
    ....
  40. ncbi request reprint Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?
    Avichai Shimoni
    Department of Blood and Marrow Transplantation, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 41:241-50. 2002
    ..There are no randomized trials showing improved (disease-free) survival with purging. In the absence of such trials, the contribution of tumor cells in the stem cell autografts to subsequent relapse remains controversial...
  41. ncbi request reprint Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 103:4056-61. 2004
    ..48; 95% CI, 1.19-5.17; P =.02), while patients with deletion 13q had a nearly 2 times higher risk of death (HR, 1.94; 95% CI, 0.95-3.98; P =.07) after dose-reduced allogeneic stem cell transplantation...
  42. doi request reprint High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Haematologica 93:455-8. 2008
    ..002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT...
  43. ncbi request reprint Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Hamburg, Germany
    Br J Haematol 129:631-43. 2005
    ..0001). We conclude that alemtuzumab produced less acute GvHD, but higher probability of relapse. The data implicated a major role of KIR-ligand mismatched transplantation in multiple myeloma...
  44. ncbi request reprint Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 104:3361-3. 2004
    ..The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease...